Marketed for adults all over the world, this drug now has the European green light but remains at the door in Canada, Japan and the United States.
Novartis has obtained marketing authorization from the European Commission for its Cosentyx for moderate to severe plaque psoriasis in children aged six to 18 years. The multinational pharmaceutical company recalls that two advanced clinical studies have demonstrated the effectiveness of this treatment on the quality of the skin, as well as a favorable risk profile.
“The impact of psoriasis in children is much deeper than the skin and can cause lifelong disorders,” insists Todd Fox, quoted in the press release issued on Monday. In addition to itching and fatigue, the disease generates a feeling of stigma.
Widely approved against psoriasis in adults worldwide, Cosentyx is not yet approved in pediatrics in the United States, Canada or Japan.
Posted: 08/03/2020, 8:40 AM